- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Gilead Honored at Pharm Exec Brand of the Year Event
The company picked up the Pharm Exec Brand of the Year award last week at the iPharma event in New York.
Gilead's Senior Director for HCV Marketing, Jason Levine, proudly accepted the Pharm Exec Brand of the Year award last week at iPharma 2015.
Pharm Exec's 31 Editorial Advisory Board (EAB) members voted unanimously for the two-punch hepatitis C treatment, Sovaldi and Harvoni, to take this year's title. They were by Gilead Science’s commitment to a strong franchise in anti-viral therapies through clinically useful drug combinations whose tolerability appeals to patients, and by the $10.3 billion in US sales posted by Sovaldi in 2014!
Pharm Exec Editor-in-Chief William Looney was on hand to present Jason with his award at a glittering event at Broadway's Crown Plaza Hotel in New York.
For the full story of Pharm Exec's 2015 Brand of the Year, click here.
Gilead's Senior Director for HCV Marketing, Jason Levine (left), accepts the Pharm Exec Brand of the Year award from Editor-in-Chief William Looney.
